AbbVie grabs SHP2 inhibitors from China's Jacobio; Chi-Med set on US filing of surufatinib
→ AbbVie has found its next targeted cancer therapy in China, licensing a suite of SHP2 inhibitors from Beijing-based Jacobio. A key node on the RAS/MAP kinase pathway, SHP2 helps drive abnormal cell growth and plays a role in cytokine production as well as immune cell response — which gives two good reasons to block it. Jacobio has so far developed two early-stage oral small molecule candidates, and they will complete early clinical trials on AbbVie’s tab before handing off to the pharma giant.
→ A meeting with the FDA has given Chi-Med the confidence to submit an NDA for surufatinib, its VEGFR inhibitor, later this year. Regulators agreed that results from two studies conducted in China — covering non-pancreatic neuroendocrine tumors and pancreatic NET — plus existing data in the US are enough to support a filing, the company said. If approved, surufatinib would be the second China-developed cancer drug to arrive on the US market following BeiGene’s Brukinsa.